Home
Media

CALIXAR and VirPath develop an innovative manufacturing process for high performance influenza vaccines

A new antigens formulation against pandemic flu (A H1N1 virus) proved six times more effective than other vaccines.

Share this post

Secure and boost
your discovery programs.

Starting from native material or recombinant systems, we succeed with all types of membrane proteins: GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins.